Patient demographics and previous and current treatments for chronic ITP patients
| Demographic . | Value . |
|---|---|
| IPF (n = 24) | |
| Mean age, y (range) | 42 (0.5-82) |
| Male, no. (%) | 11 (46) |
| Previous treatment | 16 (67) |
| Steroids, no. (%) | |
| IVIG, no. (%) | 15 (63) |
| Intravenous anti-D, no. (%) | 14 (58) |
| Rituximab, no. (%) | 10 (42) |
| Other agents,* no. (%) | 9 (38) |
| Splenectomy, no. (%) | 8 (33) |
| Comparison of A-IPF and glycocalicin (n = 17) | |
| Mean age, y (range) | 53 (31-81) |
| Males, no. (%) | 8 (47) |
| Current treatment | |
| TPO-A, no. (%) | 9 (53) |
| Prednisone, no. (%) | 2 (12) |
| IVIG, no. (%) | 2 (12) |
| Prednisone and IVIG, no. (%) | 1 (6) |
| Rigel R788, no. (%) | 1 (6) |
| Danazol and MMF,† no. (%) | 1 (6) |
| No treatment, no. (%) | 1 (6) |
| Demographic . | Value . |
|---|---|
| IPF (n = 24) | |
| Mean age, y (range) | 42 (0.5-82) |
| Male, no. (%) | 11 (46) |
| Previous treatment | 16 (67) |
| Steroids, no. (%) | |
| IVIG, no. (%) | 15 (63) |
| Intravenous anti-D, no. (%) | 14 (58) |
| Rituximab, no. (%) | 10 (42) |
| Other agents,* no. (%) | 9 (38) |
| Splenectomy, no. (%) | 8 (33) |
| Comparison of A-IPF and glycocalicin (n = 17) | |
| Mean age, y (range) | 53 (31-81) |
| Males, no. (%) | 8 (47) |
| Current treatment | |
| TPO-A, no. (%) | 9 (53) |
| Prednisone, no. (%) | 2 (12) |
| IVIG, no. (%) | 2 (12) |
| Prednisone and IVIG, no. (%) | 1 (6) |
| Rigel R788, no. (%) | 1 (6) |
| Danazol and MMF,† no. (%) | 1 (6) |
| No treatment, no. (%) | 1 (6) |